Rebecca J. Brown, M.D., M.H.Sc., Lasker Tenure Track Investigator


A selection of recent and significant publications can be viewed below.

Select Publications

Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
Brown RJ, Valencia A, Startzell M, Cochran E, Walter PJ, Garraffo HM, Cai H, Gharib AM, Ouwerkerk R, Courville AB, Bernstein S, Brychta RJ, Chen KY, Walter M, Auh S, Gorden P.
J Clin Invest (2018 Aug 1) 128:3504-3516. Abstract/Full Text
Free fatty acid processing diverges in human pathologic insulin resistance conditions.
Sekizkardes H, Chung ST, Chacko S, Haymond MW, Startzell M, Walter M, Walter PJ, Lightbourne M, Brown RJ.
J Clin Invest (2020 Jul 1) 130:3592-3602. Abstract/Full Text
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.
Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T.
J Clin Endocrinol Metab (2016 Dec) 101:4500-4511. Abstract/Full Text
Leptin decreases de novo lipogenesis in patients with lipodystrophy.
Baykal AP, Parks EJ, Shamburek R, Syed-Abdul MM, Chacko S, Cochran E, Startzell M, Gharib AM, Ouwerkerk R, Abd-Elmoniem KZ, Walter PJ, Walter M, Muniyappa R, Chung ST, Brown RJ.
JCI Insight (2020 Jul 23) 5. Abstract/Full Text
Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T, Cochran E, Gorden P, Brown RJ.
J Clin Endocrinol Metab (2015 May) 100:1802-10. Abstract/Full Text

Additional Publications

Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study.
Klubo-Gwiezdzinska J, Lange M, Cochran E, Semple RK, Gewert C, Brown RJ, Gorden P.
Diabetes Care (2018 Nov) 41:2353-2360. Abstract/Full Text
Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
Brown RJ, Oral EA, Cochran E, Araújo-Vilar D, Savage DB, Long A, Fine G, Salinardi T, Gorden P.
Endocrine (2018 Jun) 60:479-489. Abstract/Full Text
Genetics of Lipodystrophy.
Lightbourne M, Brown RJ.
Endocrinol Metab Clin North Am (2017 Jun) 46:539-554. Abstract/Full Text
Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression.
Rocha N, Bulger DA, Frontini A, Titheradge H, Gribsholt SB, Knox R, Page M, Harris J, Payne F, Adams C, Sleigh A, Crawford J, Gjesing AP, Bork-Jensen J, Pedersen O, Barroso I, Hansen T, Cox H, Reilly M, Rossor A, Brown RJ, Taylor SI, McHale D, Armstrong M, Oral EA, Saudek V, O'Rahilly S, Maher ER, Richelsen B, Savage DB, Semple RK.
Elife (2017 Apr 19) 6. Abstract/Full Text
Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review.
Gupta N, Asi N, Farah W, Almasri J, Barrionuevo P, Alsawas M, Wang Z, Haymond MW, Brown RJ, Murad MH.
J Clin Endocrinol Metab (2017 Feb 1) 102:363-374. Abstract/Full Text
Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy.
Muniyappa R, Abel BS, Asthana A, Walter MF, Cochran EK, Remaley AT, Skarulis MC, Gorden P, Brown RJ.
J Clin Lipidol (2017 Mar - Apr) 11:543-550. Abstract/Full Text
Hormonal responses to non-nutritive sweeteners in water and diet soda.
Sylvetsky AC, Brown RJ, Blau JE, Walter M, Rother KI.
Nutr Metab (Lond) (2016) 13:71. Abstract/Full Text
Management of Diabetic Ketoacidosis in Severe Insulin Resistance.
Robinson C, Cochran E, Gorden P, Brown RJ.
Diabetes Care (2016 Aug) 39:e116-8. Abstract/Full Text
Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, Brown RJ.
Clin Endocrinol (Oxf) (2016 Jul) 85:137-49. Abstract/Full Text
Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.
Levenson AE, Haas ME, Miao J, Brown RJ, de Ferranti SD, Muniyappa R, Biddinger SB.
Endocrinology (2016 Apr) 157:1421-9. Abstract/Full Text
Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy.
Kassai A, Muniyappa R, Levenson AE, Walter MF, Abel BS, Ring M, Taylor SI, Biddinger SB, Skarulis MC, Gorden P, Brown RJ.
J Clin Endocrinol Metab (2016 Apr) 101:1790-7. Abstract/Full Text
Lymphoma in acquired generalized lipodystrophy.
Brown RJ, Chan JL, Jaffe ES, Cochran E, DePaoli AM, Gautier JF, Goujard C, Vigouroux C, Gorden P.
Leuk Lymphoma (2016) 57:45-50. Abstract/Full Text
Effects of Recombinant Human Leptin (Metreleptin) on Nocturnal Luteinizing Hormone Secretion in Lipodystrophy Patients.
Abel BS, Muniyappa R, Stratton P, Skarulis MC, Gorden P, Brown RJ.
Neuroendocrinology (2016) 103:402-7. Abstract/Full Text
Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P.
Expert Rev Clin Pharmacol (2016) 9:59-68. Abstract/Full Text
Leptin Does Not Mediate Hypertension Associated With Human Obesity.
Brown RJ, Meehan CA, Gorden P.
Cell (2015 Jul 30) 162:465-6. Abstract/Full Text
Mild Caloric Restriction Decreases Insulin Requirements in Patients With Type 2 Diabetes and Severe Insulin Resistance.
Meehan CA, Cochran E, Mattingly M, Gorden P, Brown RJ.
Medicine (Baltimore) (2015 Jul) 94:e1160. Abstract/Full Text
Response to comment on Sarkar et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes care 2014;37:666-670.
Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI.
Diabetes Care (2014 Oct) 37:e219-20. Abstract/Full Text
Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides.
Joseph J, Shamburek RD, Cochran EK, Gorden P, Brown RJ.
J Clin Endocrinol Metab (2014 Sep) 99:E1676-80. Abstract/Full Text
Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.
Christensen JD, Lungu AO, Cochran E, Collins MT, Gafni RI, Reynolds JC, Rother KI, Gorden P, Brown RJ.
J Clin Endocrinol Metab (2014 Aug) 99:E1493-500. Abstract/Full Text
Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease.
Payne F, Lim K, Girousse A, Brown RJ, Kory N, Robbins A, Xue Y, Sleigh A, Cochran E, Adams C, Dev Borman A, Russel-Jones D, Gorden P, Semple RK, Saudek V, O'Rahilly S, Walther TC, Barroso I, Savage DB.
Proc Natl Acad Sci U S A (2014 Jun 17) 111:8901-6. Abstract/Full Text
Estimation of insulin sensitivity in children: methods, measures and controversies.
Brown RJ, Yanovski JA.
Pediatr Diabetes (2014 May) 15:151-61. Abstract/Full Text
Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy.
Muniyappa R, Brown RJ, Mari A, Joseph J, Warren MA, Cochran EK, Skarulis MC, Gorden P.
Diabetes Care (2014 Apr) 37:1101-7. Abstract/Full Text
Challenging recruitment of youth with type 2 diabetes into clinical trials.
Nguyen TT, Jayadeva V, Cizza G, Brown RJ, Nandagopal R, Rodriguez LM, Rother KI.
J Adolesc Health (2014 Mar) 54:247-54. Abstract/Full Text
Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI.
Diabetes Care (2014) 37:666-70. Abstract/Full Text
Metreleptin improves blood glucose in patients with insulin receptor mutations.
Brown RJ, Cochran E, Gorden P.
J Clin Endocrinol Metab (2013 Nov) 98:E1749-56. Abstract/Full Text
Novel forms of lipodystrophy: why should we care?
Rother KI, Brown RJ.
Diabetes Care (2013 Aug) 36:2142-5. Abstract/Full Text
The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, Kleiner DE, Gorden P.
J Hepatol (2013 Jul) 59:131-7. Abstract/Full Text
The clinical approach to the detection of lipodystrophy - an AACE consensus statement.
Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapiador CD, Weyer C, American Association of Clinical Endocrinologists..
Endocr Pract (2013 Jan-Feb) 19:107-16. Abstract/Full Text
Low-calorie sweetener consumption is increasing in the United States.
Sylvetsky AC, Welsh JA, Brown RJ, Vos MB.
Am J Clin Nutr (2012 Sep) 96:640-6. Abstract/Full Text
Syndromic insulin resistance: models for the therapeutic basis of the metabolic syndrome and other targets of insulin resistance.
Gorden P, Zadeh ES, Cochran E, Brown RJ.
Endocr Pract (2012 Sep-Oct) 18:763-71. Abstract/Full Text
The use of low-calorie sweeteners by children: implications for weight management.
Foreyt J, Kleinman R, Brown RJ, Lindstrom R.
J Nutr (2012 Jun) 142:1155S-62S. Abstract/Full Text
Consequences of stopping and restarting leptin in an adolescent with lipodystrophy.
Kamran F, Rother KI, Cochran E, Safar Zadeh E, Gorden P, Brown RJ.
Horm Res Paediatr (2012) 78:320-5. Abstract/Full Text
Artificial sweetener use among children: epidemiology, recommendations, metabolic outcomes, and future directions.
Sylvetsky A, Rother KI, Brown R.
Pediatr Clin North Am (2011 Dec) 58:1467-80, xi. Abstract/Full Text
Uncoupling intensive insulin therapy from weight gain and hypoglycemia in type 1 diabetes.
Brown RJ, Wijewickrama RC, Harlan DM, Rother KI.
Diabetes Technol Ther (2011 Apr) 13:457-60. Abstract/Full Text
Ingestion of diet soda before a glucose load augments glucagon-like peptide-1 secretion.
Brown RJ, Walter M, Rother KI.
Diabetes Care (2009 Dec) 32:2184-6. Abstract/Full Text
Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes.
Rother KI, Brown RJ, Morales MM, Wright E, Duan Z, Campbell C, Hardin DS, Popovic J, McEvoy RC, Harlan DM, Orlander PR, Brod SA.
Diabetes Care (2009 Jul) 32:1250-5. Abstract/Full Text
Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae.
Brown RJ, Rother KI, Artman H, Mercurio MG, Wang R, Looney RJ, Cowen EW.
Arch Dermatol (2009 Jan) 145:63-6. Abstract/Full Text
Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes.
Brown RJ, Sinaii N, Rother KI.
Diabetes Care (2008 Jul) 31:1403-4. Abstract/Full Text